Agilent Technologies (NYSE:A) Price Target Raised to $150.00

Agilent Technologies (NYSE:A) had its target price raised by Barclays from $145.00 to $150.00 in a research note issued to investors on Wednesday,Benzinga reports. The firm currently has an “overweight” rating on the medical research company’s stock. Barclays‘s price target points to a potential upside of 14.17% from the stock’s previous close.

Other equities analysts also recently issued reports about the stock. Bank of America raised shares of Agilent Technologies from a “neutral” rating to a “buy” rating and cut their price target for the company from $150.00 to $145.00 in a report on Thursday, May 28th. TD Cowen raised their price objective on shares of Agilent Technologies from $147.00 to $155.00 and gave the stock a “buy” rating in a report on Thursday, May 28th. HSBC cut their target price on shares of Agilent Technologies from $180.00 to $165.00 and set a “buy” rating for the company in a research note on Wednesday, June 3rd. Robert W. Baird increased their price target on Agilent Technologies from $155.00 to $156.00 and gave the stock an “outperform” rating in a research report on Tuesday, May 26th. Finally, Morgan Stanley dropped their price target on Agilent Technologies from $180.00 to $160.00 and set an “overweight” rating for the company in a report on Tuesday, March 3rd. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating and three have given a Hold rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $161.27.

Agilent Technologies Price Performance

Shares of A traded up $4.71 during mid-day trading on Wednesday, reaching $131.38. The company had a trading volume of 257,172 shares, compared to its average volume of 2,262,858. The company has a debt-to-equity ratio of 0.43, a current ratio of 2.10 and a quick ratio of 1.62. The company has a market capitalization of $37.11 billion, a P/E ratio of 26.39, a P/E/G ratio of 2.25 and a beta of 1.26. Agilent Technologies has a twelve month low of $108.35 and a twelve month high of $160.27. The company’s 50-day moving average is $121.94 and its 200-day moving average is $126.44.

Agilent Technologies (NYSE:A) last announced its quarterly earnings results on Wednesday, May 27th. The medical research company reported $1.49 EPS for the quarter, beating the consensus estimate of $1.41 by $0.08. Agilent Technologies had a return on equity of 24.33% and a net margin of 19.55%.The business had revenue of $1.83 billion for the quarter, compared to analyst estimates of $1.80 billion. During the same quarter in the previous year, the firm earned $1.31 EPS. Agilent Technologies’s quarterly revenue was up 10.0% on a year-over-year basis. Agilent Technologies has set its FY 2026 guidance at 6.000-6.100 EPS and its Q3 2026 guidance at 1.480-1.500 EPS. On average, equities analysts anticipate that Agilent Technologies will post 6 EPS for the current year.

Institutional Trading of Agilent Technologies

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Bridgefront Capital LLC bought a new position in shares of Agilent Technologies in the 3rd quarter valued at about $1,323,000. Wellington Management Group LLP raised its stake in shares of Agilent Technologies by 4.8% during the third quarter. Wellington Management Group LLP now owns 9,380,521 shares of the medical research company’s stock worth $1,203,990,000 after buying an additional 433,342 shares during the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. raised its stake in shares of Agilent Technologies by 4.3% during the fourth quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 599,581 shares of the medical research company’s stock worth $82,712,000 after buying an additional 24,687 shares during the last quarter. Champlain Investment Partners LLC lifted its holdings in Agilent Technologies by 33.3% in the third quarter. Champlain Investment Partners LLC now owns 895,770 shares of the medical research company’s stock valued at $114,972,000 after buying an additional 223,750 shares during the period. Finally, Andra AP fonden lifted its holdings in Agilent Technologies by 32.5% in the third quarter. Andra AP fonden now owns 132,900 shares of the medical research company’s stock valued at $17,058,000 after buying an additional 32,600 shares during the period.

About Agilent Technologies

Agilent Technologies is a global provider of scientific instrumentation, consumables, software and services for laboratories across the life sciences, diagnostics and applied chemical markets. The company’s product portfolio includes analytical instruments such as liquid and gas chromatographs, mass spectrometers, spectroscopy systems, and laboratory automation solutions, together with reagents, supplies and informatics tools that support measurement, testing and data analysis workflows. Agilent also offers instrument maintenance, qualification and laboratory services designed to help customers improve productivity and comply with regulatory requirements.

Founded as a corporate spin-off from Hewlett‑Packard in 1999, Agilent has evolved through a combination of strategic restructuring and acquisitions to concentrate on life sciences, diagnostics and applied laboratories.